Literature DB >> 3702492

Apolipoproteins and coronary artery disease.

B A Kottke, A R Zinsmeister, D R Holmes, R W Kneller, B J Hallaway, S J Mao.   

Abstract

In this study, we compared the relative utility of plasma levels of cholesterol, triglycerides, high-density lipoprotein (HDL) cholesterol, and apolipoproteins in identifying men with angiographically significant coronary artery disease in a combined sample of consecutive male patients undergoing coronary angiography (N = 304) and healthy, normal male control subjects (N = 135). The plasma apolipoprotein levels were measured by using specific radioimmunoassays. We found that plasma levels of apolipoprotein A-I, followed by those of apolipoproteins A-II and B, were better discriminators than plasma cholesterol, triglycerides, or HDL cholesterol levels for identifying those with coronary artery disease. In confirmation of previous findings, the presence of coronary artery disease resulted in lower levels of apolipoproteins A-I and A-II and HDL cholesterol and higher levels of apolipoprotein B, cholesterol, and triglycerides. Linear and quadratic discriminant function analysis demonstrated that by using the age of the patients and apolipoprotein A-I, A-II, and B levels, one could correctly classify patients either as being normal or as having angiographically significant coronary artery disease in more than 75% of the cases. Thus, plasma apolipoprotein levels (especially A-I and A-II) may be considerably better markers for coronary artery disease than traditional lipid determinations.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3702492     DOI: 10.1016/s0025-6196(12)61947-8

Source DB:  PubMed          Journal:  Mayo Clin Proc        ISSN: 0025-6196            Impact factor:   7.616


  16 in total

1.  Genetic and environmental explanations for the distribution of sodium-lithium countertransport in pedigrees from Rochester, MN.

Authors:  T R Rebbeck; S T Turner; V V Michels; P P Moll
Journal:  Am J Hum Genet       Date:  1991-06       Impact factor: 11.025

2.  Estimation of Hardy-Weinberg and pairwise disequilibrium in the apolipoprotein AI-CIII-AIV gene cluster.

Authors:  M B Haviland; A M Kessling; J Davignon; C F Sing
Journal:  Am J Hum Genet       Date:  1991-08       Impact factor: 11.025

3.  Prevalence and associations of the metabolic syndrome among patients prescribed clozapine.

Authors:  M Ahmed; I Hussain; S M O'Brien; B Dineen; D Griffin; C McDonald
Journal:  Ir J Med Sci       Date:  2008-05-07       Impact factor: 1.568

Review 4.  Guidelines for the detection of high-risk lipoprotein profiles and the treatment of dyslipoproteinemias. Canadian Lipoprotein Conference Ad Hoc Committee on Guidelines for Dyslipoproteinemias.

Authors: 
Journal:  CMAJ       Date:  1990-06-15       Impact factor: 8.262

5.  Genetic analysis of apolipoprotein A-I in two dietary environments.

Authors:  J Blangero; J W MacCluer; C M Kammerer; G E Mott; T D Dyer; H C McGill
Journal:  Am J Hum Genet       Date:  1990-09       Impact factor: 11.025

Review 6.  The effect of exercise on lipid metabolism in men and women.

Authors:  L Goldberg; D L Elliot
Journal:  Sports Med       Date:  1987 Sep-Oct       Impact factor: 11.136

7.  Cardiovascular risk determination: discrepancy between total cholesterol evaluation and two compound laboratory indices in Norway.

Authors:  J E Berg; A T Høstmark
Journal:  J Epidemiol Community Health       Date:  1994-08       Impact factor: 3.710

8.  The gender-specific apolipoprotein E genotype influence on the distribution of lipids and apolipoproteins in the population of Rochester, MN. I. Pleiotropic effects on means and variances.

Authors:  S L Reilly; R E Ferrell; B A Kottke; M I Kamboh; C F Sing
Journal:  Am J Hum Genet       Date:  1991-12       Impact factor: 11.025

9.  Changes in helical content or net charge of apolipoprotein C-I alter its affinity for lipid/water interfaces.

Authors:  Nathan L Meyers; Libo Wang; Olga Gursky; Donald M Small
Journal:  J Lipid Res       Date:  2013-05-13       Impact factor: 5.922

10.  Effects of treatment with verapamil SR and captopril on the lipid profile of hypertensive patients.

Authors:  M Catalano; C Cislaghi; G Carzaniga; A Aronica; R Seregni; A Libretti
Journal:  Drugs       Date:  1992       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.